RxDoctor Payments DataLook up a doctor →

Terrence Triplett, MD

Family Medicine · Huntington, WVNPI 1518902246

Payments from drug & device makers

$15,111in general payments, 2019–2025

Across 1,117 payments — averaging $13.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Novartis$1K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$971
  • plus $7K from 53 others

What the payments were for

  • Food & beverage$15,100100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)75$2,097
GSK93$1,350
Novartis89$1,212
AbbVie(2 entities)90$1,192
Novo Nordisk135$1,142
Lilly USA, LLC65$971
E.r. Squibb & Sons, L.L.C.62$673
Amgen(2 entities)58$668
Pfizer61$630
Johnson & Johnson(2 entities)84$623
Esperion Therapeutics, Inc.26$408
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC27$330
Amarin Pharma, Inc.26$322
Boehringer Ingelheim24$321
Paratek Pharmaceuticals, Inc.15$260
Shield Therapeutics Inc10$254
Takeda Pharmaceuticals U.S.A., Inc.17$238
Teva Pharmaceuticals USA, Inc.13$201
Otsuka America Pharmaceutical, Inc.16$199
Avanir Pharmaceuticals, Inc.19$163
Dexcom, Inc.10$159
Vifor Pharma, Inc.11$138
Argenx US, Inc.7$135
Biohaven Pharmaceutical Holding Company Ltd.6$112
Bayer6$107
Sunovion Pharmaceuticals Inc.6$94
Mylan Specialty L.p.4$86
Biohaven Pharmaceuticals, Inc.5$84
Sanofi-aventis U.S. LLC5$80
Intercept Pharmaceuticals, Inc.5$77
Kowa Pharmaceuticals America, Inc.5$64
Merck3$62
Lundbeck LLC3$60
Abbott3$57
Daiichi Sankyo Inc.3$52
Smith+Nephew2$33
Endo Pharmaceuticals Inc.2$33
Astellas Pharma US Inc2$30
Shire North American Group Inc2$29
Ironwood Pharmaceuticals, Inc2$29
Aurinia Pharma U.S., Inc.1$28
Genentech USA, Inc.2$27
Philips North America LLC1$23
Ardelyx, Inc.1$22
Insulet Corporation1$21
Scpharmaceuticals Inc.1$19
Medtronic1$19
Ferring Pharmaceuticals Inc.1$18
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Exact Sciences1$18
Sanofi Pasteur Inc.1$16
Amneal Pharmaceuticals LLC1$15
Abiomed1$14
Incyte Corporation1$14
Phathom Pharmaceuticals, Inc.1$14
Corcept Therapeutics1$14
Eisai Inc.1$14
Shionogi Inc1$12
Cequr Corporation1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,111 in reported general payments places this provider in the 95th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$215,718
Medicare patients
636
Services billed
3,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide186$260,515
EliquisApixaban232$239,160
TrulicityDulaglutide49$90,220
JardianceEmpagliflozin56$80,850
XareltoRivaroxaban72$80,518
RinvoqUpadacitinib12$75,936
JanuviaSitagliptin Phosphate36$53,793
MounjaroTirzepatide31$41,867
FarxigaDapagliflozin Propanediol22$36,025
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$32,005
EntrestoSacubitril/Valsartan33$29,764
RybelsusSemaglutide13$29,074
NexlizetBempedoic Acid/Ezetimibe33$23,689
LinzessLinaclotide16$19,612
Breo ElliptaFluticasone/Vilanterol32$18,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,142$289,590199 claims
PfizerEliquis, Dilantin$630$242,783245 claims
Lilly USA, LLCTrulicity, Mounjaro$971$132,08680 claims
AbbVieRinvoq, Linzess$1,192$95,54828 claims
Boehringer IngelheimJardiance, Spiriva Respimat$321$89,55069 claims
Johnson & JohnsonXarelto$623$80,51872 claims
MerckJanuvia$62$53,79336 claims
GSKTrelegy Ellipta, Breo Ellipta$1,350$50,42365 claims
AstraZenecaFarxiga, Brilinta, Symbicort$2,097$45,83550 claims
NovartisEntresto$1,212$29,76433 claims
Esperion Therapeutics, Inc.Nexlizet$408$23,68933 claims
Astellas Pharma US IncMyrbetriq$30$15,37213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →